Corcept Therapeutics (CORT) AI Stock Analysis

• Market Cap: $7.68B
• Dividend Yield: N/A
• Average Volume (3M): 2.09M
• Price to Earnings (P/E): 60.0
• Beta (1Y): 0.29
• Revenue Growth: 30.93%
• EPS Growth: 11.78%
• Country: US
• Employees: 500
• Sector: Healthcare
• Sector Strength: 46
• Industry: Biotechnology
• EPS (TTM): 0.17
• Shares Outstanding: 105,503,430
• 10 Day Avg. Volume: 1,421,293
• 30 Day Avg. Volume: 2,094,391
• PEG Ratio: -9.32
• Price to Book (P/B): 10.74
• Price to Sales (P/S): 0.00
• P/FCF Ratio: 42.18
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: $138.25
• Price Target Upside: 96.85% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 4

Corcept Therapeutics demonstrates impressive financial strength with significant revenue and profit growth, supported by a solid balance sheet with minimal debt. Positive technical trends support the stock's upward momentum. However, a high P/E ratio suggests potential overvaluation, and risks from net income decline and patent litigation could impact future performance.

Positive Factors

Product Development

Corcept plans to file the NDA for relacorilant in platinum-resistant ovarian cancer, which has a high likelihood of approval and potential to be a blockbuster.

Product Performance

Relacorilant achieves strong progression-free survival (PFS) and overall survival (OS) in ovarian cancer.

Strategic Opportunities

Corcept is actively pursuing multiple oncology opportunities beyond just one indication, suggesting diversified potential for growth.

Negative Factors

Financial Performance

The company reported total revenues of approximately $157.2M for 1Q25, lower than consensus estimate of $177.9M.

Market Competition

The company's authorized generic scripts continue to increase, which will offset the impact of the lower priced generic.

Sales Challenges

1Q sales of Korlym are expected to be weak sequentially due to the seasonal need for prior-authorization re-ups with payers and a distribution hiccup from 4Q.

Corcept Therapeutics Business Overview & Revenue Model

Company Description

Corcept Therapeutics (CORT) is a pharmaceutical company specializing in the development and commercialization of drugs that modulate the effects of cortisol. The company's primary focus is on developing treatments for severe metabolic, oncologic, and psychiatric disorders. Its flagship product, Korlym, is approved for the control of hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing's syndrome.

How the Company Makes Money

Corcept Therapeutics generates revenue primarily through the sales of its FDA-approved medication, Korlym. The company targets patients with Cushing's syndrome, a condition characterized by excessive cortisol levels, providing a niche market for its product. Revenue is generated through direct sales to specialty pharmacies and distributors that supply healthcare providers and patients. Additionally, the company invests in research and development to expand its product offerings and potentially introduce new medications to market, which could diversify and increase its revenue streams in the future. Corcept's partnerships with research institutions and healthcare organizations also contribute to its development pipeline, although these are not primary revenue sources.

Corcept Therapeutics Financial Statement Overview

Summary

Corcept Therapeutics has shown robust financial performance with strong revenue growth and a high gross profit margin. The balance sheet is solid with minimal debt and high equity, although there is some pressure on operational efficiency as indicated by a slight decline in EBIT margin. Cash flow metrics are stable but show a minor decrease.

Income Statement

Corcept Therapeutics has demonstrated strong revenue growth, with a 70.6% increase from 2021 to 2024 and a TTM revenue of $685.45 million. The company's gross profit margin remains impressive at approximately 98% consistently over the periods. However, there was a slight decline in EBIT margin from 19.7% in 2024 to 16.2% in the TTM, indicating some pressure on operational efficiency. Net profit margin stayed robust at around 19.4% in the TTM, showing stable profitability.

Balance Sheet

The company's balance sheet is strong, with a low debt-to-equity ratio of 0.01 and a high equity ratio of 80.7% in the TTM. Stockholders’ equity has shown consistent growth, increasing from $375.81 million in 2021 to $683.29 million in the TTM. This indicates a solid financial foundation with minimal leverage and significant equity backing.

Cash Flow

Operating cash flow remains healthy, with a slight decrease from $198.07 million in 2024 to $179.44 million in the TTM. Free cash flow has also decreased but remains positive at $177.16 million in the TTM. The operating cash flow to net income ratio is strong, indicating effective cash conversion from earnings, although there's a decline in free cash flow compared to previous years.

Breakdown
TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement		Total Revenue
685.45M	675.04M	482.38M	401.86M	365.98M	353.87M
	Gross Profit
674.70M	664.16M	475.89M	396.47M	360.70M	348.29M
	EBIT
110.87M	136.95M	107.28M	112.63M	124.48M	128.20M
	EBITDA
111.33M	136.95M	108.32M	112.63M	124.48M	130.44M
	Net Income Common Stockholders
132.85M	139.73M	106.14M	101.42M	112.51M	106.01M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
410.76M	383.33M	368.22M	436.62M	335.81M	476.89M
	Total Assets
655.93M	840.55M	621.52M	583.43M	423.76M	571.73M
	Total Debt
76.00K	6.94M	151.00K	1.14M	526.00K	2.55M
	Net Debt
-149.67M	-120.73M	-135.40M	-435.48M	-335.29M	-474.34M
	Total Liabilities
108.07M	160.96M	114.81M	81.59M	47.95M	48.39M
	Stockholders Equity
547.86M	679.59M	506.70M	501.84M	375.81M	523.34M
Cash Flow		Free Cash Flow
177.16M	195.90M	126.90M	119.91M	167.42M	150.73M
	Operating Cash Flow
179.44M	198.07M	127.04M	120.32M	167.89M	151.97M
	Investing Cash Flow
-171.76M	-177.60M	90.91M	-114.33M	136.13M	-119.26M
	Financing Cash Flow
-67.61M	-28.35M	-148.72M	-17.28M	-302.59M	12.21M

Corcept Therapeutics Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 70.23
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CORT, the sentiment is Positive. The current price of 70.23 is above the 20-day moving average (MA) of 69.49, above the 50-day MA of 66.26, and above the 200-day MA of 53.86, indicating a bullish trend. The MACD of 1.00 indicates Positive momentum. The RSI at 50.58 is Neutral, neither overbought nor oversold. The STOCH value of 43.90 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for CORT.

Corcept Therapeutics Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
HALO	78 Outperform	$7.34B	17.30	147.06%	―	25.65%	57.10%
CORT	76 Outperform	$7.68B	59.96	21.52%	―	30.93%	11.78%
TECH	70 Outperform	$7.54B	50.61	6.53%	0.64%	4.72%	-35.33%
MDGL	56 Neutral	$6.55B	―	-50.16%	―	―	21.83%
SRPT	55 Neutral	$3.56B	19.61	-23.61%	―	59.15%	-1881.09%
Sector *	52 Neutral	$5.15B	3.56	-42.52%	2.83%	14.56%	-0.53%
LEGN	47 Neutral	$5.76B	―	-15.45%	―	119.97%	67.21%

Corcept Therapeutics Corporate Events

Corcept Therapeutics Reports Q1 2025 Financial Results

On May 5, 2025, Corcept Therapeutics announced its financial results for the first quarter of 2025, reporting a revenue of $157.2 million, an increase from $146.8 million in the same period last year. Despite a record number of prescriptions, the company’s net income per share decreased due to initial fulfillment issues by its specialty pharmacy vendor. The company reiterated its 2025 revenue guidance of $900-$950 million. Corcept’s clinical development highlights include progress towards FDA approval for relacorilant in hypercortisolism and upcoming NDA submissions for relacorilant in platinum-resistant ovarian cancer. The company is also advancing studies in ALS and MASH, with significant findings from its DAZALS study showing improved survival rates for ALS patients on dazucorilant.

Spark’s Take on CORT Stock

According to Spark, TipRanks’ AI Analyst, CORT is a Outperform.

Corcept Therapeutics scores well due to its strong financial performance and positive technical indicators. While the valuation is a concern due to its high P/E ratio, the earnings call reveals a strong growth outlook, supported by substantial cash reserves and advancements in its drug pipeline. The legal challenges and operational issues are minor setbacks in an otherwise strong profile.

To see Spark’s full report on CORT stock, click here.

Corcept Therapeutics Reports Strong 2024 Financial Results

On February 26, 2025, Corcept Therapeutics announced its financial results for the fourth quarter and full year 2024, reporting a 40% increase in revenue to $675 million and a 33% rise in net income to $141.2 million compared to 2023. The company highlighted significant progress in its clinical development programs, including the submission of a New Drug Application for relacorilant for hypercortisolism and promising results from various studies, positioning relacorilant as a potential new standard of care. The announcement underscores Corcept’s strong financial performance and strategic advancements in its clinical pipeline, which could enhance its market position and impact stakeholders positively.